Twitter Facebook LinkedIn YouTube

Rapid Dose (CSE:DOSE) New Listing

Video Platform Video Management Video Solutions Video Player

The company, through its subsidiaries, provides proprietary enhanced drug delivery technologies

Additional Information:

Company: Rapid Dose
Website: http://www.rapid-dose.com
Stock Symbol: CSE: DOSE
Date Published: Dec 17, 2018
Transcript: Available

Video Transcript:

I’m Nadika Vissy for Investmentpitch Media

Rapid Dose is one of the latest new listing on the Canadian Securities Exchange, trading under the symbol “DOSE”, following a reverse takeover of TSX Venture Exchange listed Acme Resources.

The company, through its subsidiaries, provides proprietary enhanced drug delivery technologies.

Through its subsidiary, it owns a proprietary oral fast-dissolving drug delivery system, QuickStrip™.

By placing the strip under the tongue, inside the cheek, or directly on the tongue and allowing it to dissolve for a few seconds, the active molecule is released from the strip and rapidly delivered across the tissue into the blood stream.

The advantage of this type of delivery is that the active ingredient avoids being degraded by dissolution in the highly
acidic environment of the stomach, or modified by first-pass metabolism in the liver.

QuickStrip is capable of rapidly releasing a variety of pharmaceuticals, emulsified oils and over-the-counter medicines directly into the blood stream.

The proprietary oral and non-invasive drug delivery technology is designed for applications of nutraceuticals, cannabis, active pharmaceutical ingredients, and other healthcare products.

The company has recently started selling natural healthcare products including vitamin B12 and caffeine in Canada and the United States.

Mark Upsdell, CEO, stated: "The RDT team is excited to begin trading on the Canadian Securities Exchange today. The RDT team is grateful to the former directors and officers of ACME Resources Corp. and to its shareholders for the genesis to what is a culmination of two years of efforts to create a world class bio-technology company. We would also like to express our gratitude to all those stakeholders and participants who have helped us reach this day, including but not limited to our industry partners, investors and advisors. We look forward to implementing our marketing and development strategy in order to realize the growth potential of this enterprise."

As of August 31, 2018, the company had a cash balance of $6,037,000 following private placement financings which raised gross proceeds of $7,056,000.

The shares are currently trading at $1.20.

For more information, please visit the company’s website at www.rapid-dose.com, contact Mark Upsdell, CEO, at 416-477-1052 or email info@rapid-dose.com.

I’m Nadika Vissy for Investmentpitch Media